Research advances of the leukemia animal models

Abstract

Abstract: Leukemia animal models are often used in the research of cancer drug. Early leukemia animal models had low degree of fitting to the condition of human leukemia. However, as the research of pathogenesis of leukemia developed, the degree of fitting is getting better. A few kinds of leukemia mouse models and their research advances are shown in this review. The research of the high similarity leukemia animal models will contribute to the improved understanding and treatment of these cancers.

Key words: leukemia, animal model, advance

CLC Number:

R733.7

YANG Lin-cheng, HE Yi-lei, LI Wei-dong. Research advances of the leukemia animal models[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1416-1421.

References

[1] Vinay K, Abul KA, Nelson F, et al. The hematopoietic and lymphoid system[M]//Qihui Zhai. Textbook of pathology. Peking: Peking University Medical Press, 2009:275-299.
[2] Keating MJ. Leukemia: A model for drug development[J]. Clin Cancer Res,1997, 3(12 Pt 2): 2598-2604.
[3] Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XII on the criteria and kinetics associated with “curability” of experimental leukemia[J]. Cancer Chemother Rep,1964, 35: 1-111.
[4] Gilliland DG. Hematologic malignancies[J]. Curr Opin Hematol,2001, 8(4): 189-191.
[5] Olivier K, Francoise M. From Mice to Human: The "Two-Hit Model" of Leukemogenesis[J].Cell Cycle,2006, 5(6): 569-570.
[6] Moreau-Gachelin F, Tavitian A, Tambourin P, et al. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias[J]. Nature, 1988, 331(6153): 277-280.
[7] Klemsz MJ, McKercher SR, Celada A, et al. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene[J]. Cell, 1990, 61(1): 113-124.
[8] Kosmider O, Denis N, Lacout C, et al. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice[J]. Cancer Cell, 2005, 8(6): 467-478.
[9] Ruibao R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model[J]. Oncogene,2002, 21(56): 8629-8642.
[10] Ren R. Dissecting the molecular mechanism of chronic myelogenous leukemiausing murine models[J]. Leuk Lymphoma, 2002, 43(8): 1549-1561.
[11] Ren R. Modeling the dosage effect of oncogenes in leukemogenesis[J]. Curr Opin Hematol, 2004, 11(1): 25-34.
[12] Wong S, Witte ON. Modeling Philadelphia chromosome positive leukemias[J]. Oncogene, 2001, 20(40): 5644-5659.
[13] Druker BJ, Sawyers CL, Capdeville R, et al. Chronic myelogenous leukemia[J]. Hematology Am Soc Hematol Educ Program, 2001: 87-112.
[14] Goldman JM. Initial treatment for patients with CML[J]. Hematology Am Soc Hematol Educ Program,2009: 453-460.
[15] Greaves MF. Differentiation linked leukemogenesis in lymphocytes[J]. Science,1986, 234(4777): 697-704.
[16] Champlin R, Gale RP. Acute lymphoblastic leukemia: Recent advances in biology and therapy[J]. Blood,1989, 73(8): 2051-2066.
[17] Pui CH. Childhood leukemias[J]. N Engl J Med,1995, 332(24): 1618-1630.
[18] Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults[J]. Blood, 1995, 85(5): 1151-1168.
[19] Hunger, SP, Lu X, Devidas M, et al. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group[J]. J Clin Oncol, 2012, 30(14): 1663-1669.
[20] Kamel-Reid S. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in SClD mice[J]. Blood, 1991, 78(11): 2973-2981.
[21] Skorski T, Nieborowska-Skorska M, Calabretta B. A model of Ph positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice[J]. Folia Histochem Cytobiol, 1992, 30(3): 91-96.
[22] Fatih M, Uckun. Severe Combined Immunodeficient Mouse Models of Human Leukemia[J]. Blood,1996, 88(4): 1135-1146.
[23] Bhadri. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia[J]. BMC Genomics, 2011, 12: 565-577.
[24] Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia[J]. Adv Exp Med Biol, 1999, 457: 593-605.
[25] Brian JS. Murine Models of CLL: Role of microRNA-16 in the NZB mouse model[J]. Br J Haematol, 2007, 139(5): 645-657.
[26] Hamano Y, Hirose S, Ida A, et al. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice[J]. Blood,1998, 92(10): 3772-3779.
[27] Phillips JA, Mehta K, Fernandez C, et al. The NZB mouse as a model for chronic lymphocytic leukemia[J]. Cancer Res,1992, 52(2): 437-443.
[28] Ramachandra S, Metcalf RA, Fredrickson T, et al. Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL[J]. J Clin Invest,1996, 98(8): 1788-1793.
[29] Raveche ES. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice[J]. Blood,2007, 109(12): 5079-5086.
[30] Herron LR, Coffman RL, Bond MW, et al. Increased autoantibody production by NZB/NZW B cells in response to IL-5[J]. J Immunol,1988, 141(3): 842-848.
[31] Pekarsky Y, Zanesi N, Aqeilan RI, et al. Animal models for chronic lymphocytic leukemia[J]. J Cell Biochem,2007, 100(5): 1109-1118.
[32] Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state[J]. Leukmia, 2006, 20(2): 280-285.
[33] Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma[J]. Proc Natl Acad Sci USA,2002, 99(22): 14392-14397.
[34] Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia[J]. Blood, 2001, 98(6): 1979-1981.
[35] Cook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing[J]? Cancer Metastasis Rev, 2013, 32(1/2): 63-76.